Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study

Abstract:

[Not available, this was published as a letter to the editor]

Authors: Bringhen S, Mina R, Cafro AM, Liberati AM, Spada S, Belotti A, Gaidano G, Patriarca F, Troia R, Fanin R, De Paoli L, Rossi G, Lombardo A, Bertazzoni P, Palumbo A, Sonneveld P, Boccadoro M.

Main author: Bringhen

Publication date: January 2018

Journal details: Leukemia. 2018 Jan 30

DOI: 10.1038/s41375-018-0024-1

Link: https://www.nature.com/articles/s41375-018-0024-1

Connected Trials: EMN07